Clinical Trial of BCD-148 and Soliris® for the Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria

Inclusion criteria

• He/she gave written informed consent.
• Male or female ≥18 and ≤65 years of age.
• PNH diagnosis documented by flow cytometry data at screening .
• PNH granulocyte clone size ≥10% (according to flow cytometry performed at screening).
• Lactate dehydrogenase (LDH) level ≥1.5 times the upper limit of normal (ULN) at screening and at least one of the following symptoms/syndromes: hemoglobinuria, thrombotic complications, transfusion-dependent chronic hemolysis, anemic syndrome, acute kidney injury episodes or chronic kidney disease, pulmonary hypertension, and signs of smooth muscle dystonia (e.g., abdominal pain, dysphagia, erectile dysfunction, and etc.) within three months before informed consent.
• Platelet count ≥30х109/L at screening.
• Absolute count of neutrophil granulocytes ≥0.75х109/L at screening.
• Willingness to undergo vaccination against Neisseria meningitidis during the screening period and at least 14 days before the first administration of an investigational product .
• If immunosuppressive drug products are used, the duration of this therapy should be at least three months by informed consent date.
• The willingness of patients and their sexual partners of childbearing potential to use reliable contraception methods starting from the informed consent, throughout the study, and for four weeks after the last dose of an investigational product. This requirement does not apply to patients who underwent surgical sterilization and women with menopause established more than two years ago. Reliable contraception methods include one barrier method in combination with one of the following: spermicides or an intrauterine device.
• The patient is able, in the Investigator's opinion, to follow study procedures.

Exclusion criteria

• History of meningococcal infection (either well-documented or according to oral information provided by a patient).
• Other well-documented complement deficiencies (except for those concerning complement component 5).
• History of bone marrow transplantation (either well-documented or according to oral information provided by a patient).
• HIV, hepatitis B, active hepatitis C, and syphilis .
• A patient with newly diagnosed or relapsing aplastic anemia and/or progressive bone marrow failure with indications for allogeneic bone marrow transplantation or combined immunosuppressive therapy within 6 months after informed consent.
• Acute infection (either well-documented and/or according to oral information provided by a patient) within 4 weeks before informed consent and/or during the screening period and/or relapse of chronic disease at the moment of informed consent and/or during the screening period .
• Any other chronic diseases present at the time of the informed consent which can negatively affect the patient's safety during the study, in the Investigator' opinion.
• Use of eculizumab and/other anti-C5 monoclonal antibodies within three months before informed consent .
• Hypersensitivity to any of BCD-148/Soliris® ingredients, murine proteins and other ingredients of these drug products, and to any of meningococcal vaccine ingredients.
• Documented malignancy, except for cured basal cell carcinoma or cervical carcinoma in situ .
• A known alcoholic or drug abuse or signs of present alcoholic/drug abuse that, in the Investigator's opinion, can be a contraindication to treatment with an investigational product or limit treatment compliance.
• Participation in other clinical studies within 30 days before informed consent and during this study.
• Pregnancy or lactation or planning for pregnancy/paternity during the clinical study.